Addendum
Beclometasone/formoterol/glycopyrronium (asthma) - Addendum to Commission A21-18
Report documents
-
Addendum
Beclometasone/formoterol/glycopyrronium (asthma) - Addendum to Commission A21-18
Dossier assessment
Indication:
Adult patients with asthma whose disease is not adequately controlled with a combination of medium- or high-dose ICS and LABA, and who experienced one or more asthma exacerbations in the previous year
Result of dossier assessment:
Unchanged after addendum:
- Medium-dose ICS/LABA therapy: added benefit not proven.
- High-dose ICS/LABA therapy: added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
19 December 2024: The G-BA’s decision of 5 August 2021 was cancelled.
Project details
- Project no.
- A21-85
- Commission
- Commission awarded on 22.06.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Beclometasone/formoterol/glycopyrronium (asthma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed